Mark E. McGovern - Concepedia

Author

Mark E. McGovern

Also Known As

M E McGovern, M McGovern, M. E. Mcgovern, M. McGovern, M.E. McGovern, Mark E McGovern, Mark E Mcgovern, Mark E. McGovern, Mark E. Mcgovern, Mark Edward McGovern

189

Publications

6.4K

Citations

H-Index

188

Concepts

All Affiliations

Harvard Global Health Institute Queen's University Belfast Bristol-Myers Squibb (United States)Wake Forest University Environment and Climate Change Canada

About

Mark E. McGovern is an author at Harvard Global Health Institute specializing in medicine, cardiovascular disease, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	2.6K
2	Engineering	13	14	1.4K
3	Business	2	2	559
4	Education	2	2	42
5	Health Sciences	2	2	634

Mark E. McGovern

Publications

5.4K

Citations

H-Index

Page 1

	Year	Citations
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II) John R. Crouse, Robert P. Byington, M. Gene Bond, The American Journal of Cardiology Metabolic SyndromeLipid DisorderCardiovascular DiseaseMedicinePhysiology	1995	613
Air pollution removal by urban forests in Canada and its effect on air quality and human health David J. Nowak, Satoshi Hirabayashi, Marlene Doyle, Urban forestry & urban greening EngineeringEnvironmental EngineeringEnvironmental HealthUrban Air QualityAir Quality	2017	528
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events Bertram Pitt, G.B.John Mancini, Stephen G. Ellis, Journal of the American College of Cardiology Coronary ArteriesVascular DiseaseCardiovascular DiseaseAtherosclerosis ProgressionPharmacology	1995	428
Role of Solvent on the Silanization of Glass with Octadecyltrichlorosilane Mark E. McGovern, Krishna M. R. Kallury, Michael Thompson Langmuir Materials ScienceChemical EngineeringEngineeringGlass-forming LiquidGlass Transition	1994	348
Increasing ambient temperature reduces emotional well-being Clemens Noelke, Mark E. McGovern, Daniel J. Corsi, Environmental Research	2016	235
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix. Moti L. Kashyap, Mark E. McGovern, Kathleen Berra, The American Journal of Cardiology Drug SafetyCardiovascular DiseaseMedicinePublication CommitteePharmacotherapy	2002	234
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Paul L. Canner, Curt D. Furberg, Michael L. Terrin, The American Journal of Cardiology Healed Myocardial InfarctionGlycemic StatusCoronary Drug ProjectCardiovascular DiseaseDiabetes	2005	226
Genosensor technology and the detention of interfacial nucleic acid chemistry Mengsu Yang, Mark E. McGovern, Michael Thompson Analytica Chimica Acta Dna NanotechnologyNucleic Acid ChemistryEngineeringGenosensor TechnologyNatural Sciences	1997	166
The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea David E. Bloom, Simiao Chen, Michael Kühn, The Journal of the Economics of Ageing Disease ManagementChronic Disease ManagementHealth EconomicsHealth PolicySouth Korea	2018	155
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE]) Harold Bays, Carlos A. Dujovne, Mark E. McGovern, The American Journal of Cardiology Cardiovascular DiseaseMedicineCardiovascular PharmacologyClinical TrialsHyperlipidemia	2003	153

Page 1